lation of MHC-I inside HeLa cells is not blocked by dominantnegative dynamin (39) , a protein required for most types of endocytic processes (8, 20, 43) . Moreover, Nef-mediated reduction in steady-state MHC-I cell surface levels is not affected by dominant-negative dynamin (24) . (Albeit, MHC-I might be endocytosed via a recently discovered ARF-6-dependent mechanism [4, 36] and data are conflicting as to whether dominant-negative dynamin affects this pathway [1, 9] .) Finally, there is direct evidence that Nef can inhibit transport to the cell surface in astrocytic cells (39) . Thus, it is possible that there are two pathways contributing to Nef-mediated MHC-I downmodulation or that Nef behaves in a cell type-specific manner. We and others (24, 25, 37) have found that downmodulation of the MHC-I HLA-A2 allotype in HeLa cells (and other adherent cell lines) ranges from 2-to 4-fold, whereas downmodulation of HLA-A2 in T cells can range up to 200-fold (7). It is not clear whether these apparent cell type differences result from qualitative or quantitative differences in Nef function.
To further characterize the two pathways contributing to Nef-mediated MHC-I downmodulation, and to characterize any cell type-specific differences, we directly compared the relative effects of Nef on HLA-A2 expression in HeLa cells and T cells expressing equal amounts of Nef protein. We found that T cells were significantly more active at supporting Nefmediated HLA-A2 downmodulation than HeLa cells, regardless of whether Nef was expressed in the context of HIV infection or alone. An examination of the mechanism of Nefmediated HLA-A2 downmodulation in T cells revealed that the main effect of Nef was to inhibit HLA-A2 transport to the cell surface.
MATERIALS AND METHODS
Antibodies. The monoclonal antibody BB7.2, which specifically recognizes the HLA-A2 allotype of MHC-I (31), was purified, using a Hitrap protein A FF column (Pharmacia) and following the manufacturer's protocol, from ascites or HB-82 hybridoma (American Type Culture Collection) supernatant. The antibody directed at placental alkaline phosphatase (PLAP) was obtained from Biomeda. The secondary antibodies used in this study were goat anti-mouse immunoglobulin G-phycoerythrin (PE; Caltag) for HLA-A2 stains and goat anti-rabbit-fluorescein isothiocyanate (Caltag) for PLAP stains. HIV-1 Nef antiserum for Western blotting was obtained from Ronald Swanstrom (AIDS Research and Reference Reagent Repository, Division of AIDS, National Institute of Allergy and Infection Diseases, National Institutes of Health) (38) .
Cell lines and culture conditions. HeLa cell lines were maintained in Dulbecco modified Eagle medium (DMEM) supplemented with 2 mM glutamine, 10% fetal bovine serum (FBS), penicillin, and streptomycin. The HeLa-A2 cell line has been described previously (12) . CEM-SS lines were maintained in RPMI medium supplemented with 2 mM glutamine, 10% FBS, penicillin, and streptomycin. To create a stable CEM-SS T-cell line expressing HLA-A2, CEM-SS T cells were transduced with a murine stem cell virus retroviral construct that contained HLA-A2 (19, 32) and, using neomycin, were selected for expression.
HLA-A2
ϩ peripheral blood mononuclear cells were isolated from a buffy coat supplied by the Lansing Red Cross and were stimulated and infected as previously described (7) .
HIV genome mutant construction and HIV transduction protocol. Viruses were prepared from HIV-1 molecular clones and used to infect T cells as previously described (7) except that they were pseudotyped with pCMV VSV-G (Nancy Hopkins, Massachusetts Institute of Technology) to allow infection of HeLa cells. Briefly, 10 6 T cells or 100,000 HeLa cells were centrifuged at 2,500 rpm in a Sorvall tabletop centrifuge for 2 h with 1 ml of high-titer HIV supernatant prepared from transfected 293 cells (7), 4 g of Polybrene/ml, and 10 mM HEPES. NL-PIenv Ϫ was constructed as follows. The SalI-NotI fragment of NLPIrev HXB (7) , containing the env open reading frame, was subcloned into pBluescript II KS. The NdeI site was filled in, disrupting the env open reading frame, and then the SalI-NotI fragment was religated back into NL-PI, creating NLPIenv Ϫ . In this virus, PLAP is inserted into the Nef open reading frame and Nef expression is restored with a downstream internal ribosome entry site, as previously described (5, 7). The nef Ϫ version of this virus was created by making a frameshift mutation at the XhoI site in nef (7) . NL-PIenv Ϫ achieved amounts of HLA-A2 downmodulation similar to those of another virus used in these studies, HXB-EP, which has PLAP inserted into the envelope open reading frame and expresses levels of Nef equivalent to those expressed by unmodified HIV molecular clones (references 5 and 7 and data not shown).
Adenovirus transduction. A replication-defective adenoviral vector expressing HIV-1 Nef (adeno-Nef) and lacking a segment of the E3 region (including E319K) was constructed as previously described by the University of Michigan Vector Core Facility (39) . The control virus (control-adeno) is identical to adeno-Nef except that it lacks the Nef open reading frame. Adenovirus transductions were performed as follows. HeLa cells or T cells were incubated with adenovirus in DMEM supplemented with 2% FBS. After 2 h, an equal volume of fresh DMEM plus 10% FBS was added. Cells were then incubated for 24 to 48 h prior to harvest. Multiplicity of infection (MOI) was based on 293 cell infectivity.
Analysis by fluorescence-activated cell sorting (FACS). To assess the level of cell surface class I molecules or PLAP, cells were incubated with primary antibody for 20 min at 4°C in FACS buffer (phosphate-buffered saline, 2% FBS, 1% HEPES, 1% sodium azide), washed, incubated with the appropriate secondary antibody (see above), washed again, and analyzed (using CELLQuest software) on a Becton Dickinson FACScan apparatus.
Western blot analysis of Nef expression levels. Cells were lysed in NP-40 lysis buffer (1% NP-40, 50 mM Tris [pH 7.3], 5 mM MgCl 2 , 1 mM phenylmethylsulfonyl fluoride), and equal amounts of protein were loaded onto a sodium dodecyl sulfate (SDS)-15% polyacrylamide gel. Samples were electroblotted onto Immobilon, blocked in 5% milk in TBS buffer (10 mM Tris [pH 8.0], 140 mM NaCl), and probed with HIV-1 Nef antiserum (see above). Blots were developed using Supersignal (Pierce) according to the manufacturer's instructions. Equal protein loading was confirmed by staining the polyacrylamide gel with Coomassie brilliant blue after transfer.
Endocytosis assays. To assess the amount of HLA-A2 internalization, HeLa cells and T cells were treated with control-adeno or adeno-Nef at the indicated MOI. Approximately 24 h later, cells were harvested and incubated with BB7.2 anti-HLA-A2 monoclonal antibody for 20 min at 4°C, washed, and placed at 37°C and 5% CO 2 for the indicated time periods in culture medium lacking serum. The cells were then washed and incubated with goat anti-mouse PE in FACS buffer containing 0.2% bovine serum albumin instead of serum. Using CELLQuest software, the cells were analyzed on a Becton Dickinson FACScan apparatus.
Recycling assays. Recycling assays were performed as described previously (24) , except that washes were performed at room temperature to avoid inhibiting recycling with cold temperature (4) . Briefly, cells were treated with controladeno or adeno-Nef at the indicated MOI. Approximately 24 h later, the cells were incubated with 150 g of cycloheximide (Sigma)/ml for 2 to 3 h in DMEM (HeLa cells) or RPMI medium (T cells) plus 10% serum. Then cells were harvested, and an aliquot was removed and placed on ice. The remainder of the samples were stripped of stainable HLA-A2 by washing in 50 mM glycine-100 mM NaCl (at pH 3.0 for HeLa cells or pH 3.4 for T cells) at room temperature. The stripped cells were then washed in phosphate-buffered saline and incubated at 37°C and 5% CO 2 in medium without serum for the indicated period of time.
(Samples were incubated without serum to avoid substitution of bovine ␤ 2 -microglobulin present in serum for the human ␤ 2 -microglobulin removed with the stripping protocol.) Cells were then stained for HLA-A2 as described above.
Intracellular transport assays. For the flow cytometric transport assay, cells were treated as described above for the recycling assay, except that samples were prepared in duplicate treatments with or without cycloheximide. To determine the amount of newly synthesized HLA-A2 appearing at each time point, the mean fluorescence intensity (MFI) of the cycloheximide-treated cells was subtracted from the MFI of the untreated cells at each time point. In addition, the background remaining after stripping at time zero was subtracted from each sample. To test the role of phosphatidylinositol (PI) 3-kinase, the indicated amount of LY294002 (Upstate Biotechnology) was added to cells at the same time as cycloheximide and was left in throughout the experiment. The biochemical transport assay protocol used was similar to that reported previously (28) . Briefly, CEM and CEM-A2 T cells were infected with VSV-G pseudotyped NLPIenv Ϫ with or without Nef expression, as previously described (7 (45), except that the immune complexes were washed with radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris [pH 8], 150 mM NaCl, 1% NP-40, 0.5% deoxycholate, 0.1% SDS, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride). The precipitated sample was eluted from the beads by boiling for 5 min in 100 l of 10% SDS. One-third was analyzed directly to assess total HLA-A2. The remaining two-thirds was diluted 20-fold in RIPA buffer and reprecipitated using avidin agarose beads (Calbiochem) for 24 h as previously described (28) . Total and cell surface HLA-A2 was then analyzed by SDSpolyacrylamide gel electrophoresis (PAGE).
RESULTS
To determine whether HeLa cells and T cells (two cell types commonly used to study Nef-mediated downmodulation) differed in their sensitivity to Nef, we examined the effects of Nef on HeLa cells stably expressing HLA-A2 (HeLa-A2) and T1 T cells that expressed endogenous HLA-A2. These cells were infected with a version of NL4-3 (NL-PIenv Ϫ ) that had been pseudotyped with VSV-G protein to allow transduction of (Fig. 1A) . Western blot analysis comparing Nef expression levels in cell lysates normalized for infection rate revealed that there was no significant difference that would explain this result (Fig. 1B) . There was no detectable downmodulation of HLA-A2 in cells treated with a control virus that lacked Nef expression (reference 7 and data not shown).
To rule out the possibility that differences in Nef activity were due to another HIV factor that might behave differently in HeLa versus T cells, we assessed downmodulation of HLA-A2 by Nef expressed alone in a replication-defective adenoviral vector. It has previously been determined that expression of Nef in this context results in specific downmodulation of wild-type HLA-A2 but not HLA-A2 mutants that do not respond to Nef (12, 39, 45) . Additionally, Nef mutants known to be defective at HLA-A2 downmodulation behaved appropriately when expressed in the adenoviral vector system (12, 39, 45) .
In agreement with the data shown in Fig. 1 
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KASPER AND COLLINS J. VIROL. Fig. 2A ). This was not due to differences in Nef expression based on 293 cell infectivity; because at the highest Nef level tested, there was more Nef protein expressed in the HeLa cell lysates than in the T-cell lysates (Fig. 2B) . Thus, it seems that T cells and HeLa cells responded differently to similar amounts of Nef protein. In both cell types, there was no detectable downmodulation by the control adenovirus, which differed only in that it lacked the nef open reading frame (data not shown).
To further explore the cell type-specific effect of Nef shown in Fig. 1 and 2 , we examined the rate of Nef-mediated HLA-A2 endocytosis, recycling, or intracellular transport in the two cell types. To assess endocytosis rates, HeLa-A2 cells and CEM-A2 cells were transduced with adeno-Nef or control-adeno, adjusted so that there were equal amounts of Nef in the HeLa cells and the CEM T cells (MOI ϭ 10,000:1 for CEM and 100:1 for HeLa). At 24 h later, the cells were stained with antibodies directed at HLA-A2 and incubated at 37°C for the indicated time to allow internalization. They were then stained with a secondary antibody conjugated to PE and assayed by flow cytometry. In agreement with prior reports (24) , there was a significant Nef-dependent stimulation of endocytosis in HeLa cells (Fig. 3A) . In HeLa cells without Nef, there was internalization of 0 to 10% of HLA-A2 in 30 min, and this increased to 35% when Nef was expressed. As reported previously, this effect of Nef was relatively small compared to the rate of internalization of an HLA-A2 molecule with a canonical endocytosis signal (YSQL) in its cytoplasmic tail. Approximately 70% of HLA-A2 molecules with a YSQL signal are removed from the cell surface in 10 min (24) .
In contrast, HLA-A2 in T cells is continuously endocytosed and recycled even without Nef expression (21, 27, 41, 42, 44, 46) . Indeed, we observed that without Nef, approximately 45% of HLA-A2 in CEM-A2 cells was internalized in 30 min (Fig.  3B) . Nef expression increased the amount of HLA-A2 internalized during this time period by only about 15% to a total of 60% internalized in 30 min (Fig. 3B) . Based on these results, it seems unlikely that this small Nef-dependent effect on endocytosis can explain the dramatic effects of Nef on steady-state HLA-A2 surface expression in T cells. In addition, these data do not explain why T cells respond to Nef more robustly than HeLa cells.
To determine whether the major effect of Nef on HLA-A2 surface levels in T cells was due to effects on recycling, we performed recycling assays, as previously described (24), using T cells or HeLa cells treated with adeno-Nef and expressing similar amounts of Nef protein. To measure the amount of HLA-A2 that was recycled under these conditions, surface HLA-A2 complexes on the plasma membrane were denatured by washing cells with an acidic buffer. By disrupting the noncovalent association between the HLA-A2 heavy and light chains, this treatment destroys the ability of HLA-A2 to be recognized by the anti-HLA-A2 monoclonal antibody BB7.2. The treated cells were then incubated at 37°C, and the appearance of recycled HLA-A2 on the cell surface was measured by flow cytometry over time. To ensure that only the recycled HLA-A2 molecules were measured, protein synthesis was inhibited by pretreatment for 2 to 3 h with cycloheximide (150 g/ml). Using this assay, we tested the effect of Nef on recycling in adeno-Nef-transduced HeLa cells (Fig. 4A) , adenoNef-transduced CEM-A2 cells (Fig. 4B) , HIV-infected primary T cells (Fig. 4C) , and HIV-infected CEM-A2 cells (Fig.  4D ). In agreement with prior experiments performed with HeLa cells (24), we did not observe significant inhibition of recycling by Nef within the error of the assay system.
To examine the relative effect of Nef on HLA-A2 intracellular transport, the appearance of newly synthesized HLA-A2 on the cell surface, with or without Nef expression, was quantified over time. This was accomplished by stripping surface HLA-A2 as described above and measuring its reappearance on the cell surface in the absence of protein synthesis inhibitors. To correct for HLA-A2 appearing on the cell surface as a result of recycling from internal compartments, a duplicate set of cycloheximide-treated samples was run in parallel. The amount of newly synthesized material transported to the cell surface was then calculated for each time point by subtracting the amount of HLA-A2 that had appeared on the cell surface as a result of recycling.
When this assay was performed using T cells treated with adeno-Nef or control-adeno, we observed a dramatic (up to eightfold) reduction of newly synthesized HLA-A2 appearing on the surface of cells expressing Nef (Fig. 5A) . This large effect of Nef on transport of newly synthesized HLA-A2 to the cell surface contrasts with the relatively small effect of Nef on endocytosis and recycling rates in T cells. Thus, it is likely that the dramatic effect of Nef on the appearance of newly synthesized HLA-A2 at the plasma membrane results primarily from a transport block rather than from extremely rapid endocytosis The effect of similar Nef levels on HLA-A2 transport to the cell surface was much less dramatic in HeLa cells. In these cells, we observed a relatively small (1.3-fold) reduction of HLA-A2 transport at similar Nef levels (Fig. 5B) . (At Nef expression levels that are higher than those which are typically required for HLA-A2 downmodulation in T cells, a greater effect of Nef on HLA-A2 transport was measured in HeLa cells [2.9-fold at an MOI of 500:1; data not shown]). Based on these data, Nef is more active in T cells than HeLa cells because it is better able to disrupt HLA-A2 transport to the plasma membrane in T cells.
To confirm the physiologic significance of these data, we asked whether there were defects in transport of HLA-A2 to the cell surface of primary T cells. This question was addressed by preparing HLA-A2 ϩ primary T cells and transducing them with HXB-EP with or without Nef expression, as previously described (7). Then, the capacity of the infected cell subset (approximately 10% of the cells as assessed by PLAP expression) to transport HLA-A2 to the cell surface was measured, using the protocol outlined above, by two-color flow cytometry. 
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We found that there was a dramatic, Nef-dependent block in transport of HLA-A2 to the surface in the PLAP ϩ Nef-expressing cells but not in the PLAP ϩ nef Ϫ cells (Fig. 5C ). These data strongly suggest that HIV disrupts the trafficking of HLA-A2 in T cells primarily by preventing transport of newly synthesized molecules to the cell surface.
To confirm these results, we used a biochemical system that more directly distinguished newly synthesized molecules from recycling molecules. Briefly, CEM-A2 cells were infected with NL-PIenv Ϫ with or without nef expression. After 48 h, most of the CEM-A2 cells treated in this manner are generally infected and downmodulate HLA-A2 approximately 50-fold (Fig. 6A) . The infected cells were pulse labeled and then surface labeled with biotin as described in Materials and Methods. They were then lysed, and HLA-A2 was immunoprecipitated using monoclonal antibody BB7.2. Two-thirds of the immunoprecipitate was reprecipitated with avidin beads to specifically pull down only the molecules that were on the cell surface. The results of this experiment, shown in Fig. 6B to E, indicate that Nef reduced the amount of newly synthesized HLA-A2 appearing on the cell surface by eightfold. As was previously reported, Nef also induced a comparatively small (approximately two-to threefold) effect on the stability of the HLA-A2 protein (37, 45) .
It was previously reported that the phosphatidylinositol (PI) 3-kinase inhibitor, LY294002, inhibits Nef's ability to block intracellular transport in astrocytic cells but not Nef's effects on CD4, supporting the idea that Nef affects MHC-I and CD4 by different mechanisms (39) . To determine whether LY294002 differentially affected Nef-mediated HLA-A2 downmodulation in HeLa cells and T cells, we transduced these cells with adeno-Nef or control-adeno and treated them with 40 or 75 M LY294002 overnight. Under these conditions, LY294002 inhibited downmodulation of HLA-A2 in astrocytic cells and T cells but not in HeLa cells (data not shown). However, we noted greater toxicity of the inhibitor for T cells than for the other cell types. In addition, the inhibitor reduced baseline HLA-A2 levels in T cells. Therefore, to confirm the effect of the inhibitor, we asked whether it had an effect when added for the shorter (4 h) time period of incubation required for the flow cytometric transport assay. Under these conditions, Nef-expressing T cells treated with the inhibitor remained defective for HLA-A2 transport to the cell surface (Fig. 7) . These data appear to rule out the simple model that Nef links MHC-I to PI 3-kinase to disrupt MHC-I trafficking and suggest that the effect of the inhibitor over longer time periods is indirect-perhaps affecting Nef localization or a posttranslational modification of Nef. 
DISCUSSION
Multiple studies have now demonstrated that HIV Nef downmodulates MHC-I and that this process affects CTL recognition in vitro (7, 47) and HIV pathogenicity in vivo (15, 30) . However, the molecular mechanism has remained unclear. In addition, the biological relevance of MHC-I downmodulation has remained controversial. This is due, in part, to the wide range of efficacy reported in the literature. These differences might result from the need for allotype-specific antibodies to distinguish the subset of MHC-I molecules affected by Nef (6, 7, 25) and the need for high Nef levels in some cell types (25, 26) . As shown here, a direct comparison reveals that similar amounts of Nef caused a much more dramatic downmodulation in T cells than in some adherent cell lines, such as HeLa cells. In T cells, Nef levels equivalent to those achieved by natural HIV genomes are sufficient to promote dramatic (up to 200-fold) effects on HLA-A2 levels in primary T cells (7) .
Nef has been reported to affect endocytosis rates in T-cell lines stably expressing Nef and to block transport of newly synthesized HLA-A2 to the cell surface in astrocytic cells transiently transduced with adeno-Nef (37, 39). However, it was not known whether both of these pathways were active in all cell types or in HIV-infected cells. Furthermore, if both pathways were active, it was not known whether one might be more important than the other. To further explore these questions, we examined Nef's effects on HLA-A2 endocytosis, recycling, and transport to the cell surface in T cells. We found that the effects of Nef on HLA-A2 transport to the cell surface were much more dramatic than its effects on endocytosis or recycling. In addition, the differential effect of Nef on HLA-A2 transport to the cell surface explained the differences in degree of downmodulation in HeLa cells versus T cells. Moreover, we were able to demonstrate that Nef blocked the transport of HLA-A2 to the cell surface in HIV-infected T cells.
The precise molecular mechanism for the greater efficacy of Nef in T cells requires further study. It is possible that HeLa cells transfected to express high levels of HLA-A2 have a relative deficiency in a required cellular factor. Alternatively, HLA-A2 and/or Nef might be processed differently in T cells. A greater understanding of why these cells behave differently is likely to provide insight into the mechanism of Nef-mediated MHC-I downmodulation and normal MHC-I biology.
To downmodulate MHC-I, Nef physically associates with the cytoplasmic tail of MHC-I (45) and might then act as an adaptor molecule, linking MHC-I with other cellular proteins that bind Nef. For example, there are a number of proteins involved in intracellular trafficking that can physically interact with Nef and are candidate factors that can affect MHC-I trafficking (e.g., PACS-1 [35] and ␤-COP [2, 34] ). Other trafficking proteins that have been reported to associate with Nef (vacuolar ATPase and adaptin complexes [AP-1 and AP-2]) might not be necessary for MHC-I downmodulation, because amino acids in Nef required for association of Nef with these molecules are not needed for MHC-I downmodulation (16, 17, 29) . Further research is needed to determine what cellular factors are important for Nef-mediated MHC-I downmodulation in T cells.
The mechanism of Nef-mediated MHC-I downmodulation contrasts with that of Nef-mediated CD4 and CD28 downmodulation. Nef is thought to reduce cell surface expression of CD4 (and CD28) by binding to their cytoplasmic tails and linking them to the endocytic apparatus via associations with adaptins and/or vacuolar ATPase (3, 11, 13, 14, 16, 18, 22, 33, 40) . It will be important for future studies to elucidate how HIV Nef is able to differentially associate with these cellular factors and use distinct mechanisms to affect the trafficking of CD4, MHC-I, and CD28.
The data presented here put the relative effect of Nef on MHC-I endocytosis and intracellular transport in perspective by using a cell type that is a natural target of HIV infection. The results of these studies highlight the need to understand the effect of Nef on inhibition of MHC-I intracellular transport to the cell surface-a new function for this complex protein.
